Solid Biosciences Reports Inducement Grant to New Senior Vice President, Human Resources
January 04, 2022 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
November 03, 2021 07:05 ET
|
Solid Biosciences Inc.
- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene...
Pathway Development Consortium Releases Draft White Paper to Facilitate AAV Gene Therapy Development
November 02, 2021 07:30 ET
|
Solid Biosciences Inc.; The Pathway Development Consortium; REGENXBIO Inc.
- Draft white paper published today by the Pathway Development Consortium provides a framework for applying the accelerated approval pathway to AAV gene therapy development - - Pathway Development...
Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit
October 21, 2021 08:00 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
September 29, 2021 07:00 ET
|
Solid Biosciences Inc.
- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post...
Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
September 23, 2021 06:00 ET
|
Solid Biosciences Inc.
- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital...
Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001
September 20, 2021 16:05 ET
|
Solid Biosciences Inc.
- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021...
Solid Biosciences to Participate at Upcoming Investor Conferences
September 20, 2021 16:01 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...
Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021
August 24, 2021 08:00 ET
|
Solid Biosciences Inc.
- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE)...
Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance
August 19, 2021 08:05 ET
|
Solid Biosciences Inc.
CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy...